GMED's Quality Score rose 1 point on Tue, Nov 3, to 10.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 2% over five years while the S&P 500 rose 74%; up 30% in the past year.
The other side, how the business stands, the timeline, and its peers, for Pro members.
| The company | Profit up 50% to $535M |
| Latest filing | 10-Q, Aug 6 |
ReportReports Thursday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 3 of its last 4 reports, +8.5% on average. Past reports ›
After its last 4 reports it closed +8.5% on average, higher 3 of 4 times.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
GMED is #19 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 19 |
Net income over four quarters: GMED $535M, MMSI $146M, HAE $96.3M, ATRC $10.6M.
Reports Thu Nov 5, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease in GAAP net income was primarily driven by the bargain purchase gain of $110.5 million recognized in the prior year quarter related to the Nevro acquisition.”
GMED's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Non-GAAP fully diluted EPS | $4.95 to $5.05 |
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | +8.7% | +1.6% | +6.0% |
| May 7, 2026 | +0.6% | -8.4% | -9.2% |
| Feb 24, 2026 | +0.5% | +4.7% | -0.2% |
Sales grew in 2025, to $2.9B. It made a profit in both years.
3 insiders sold $6.4M across 3 filings in the last 6 months. No open-market buys on record. The newest:
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: GMED is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.
“We believe that our significant competitors are Medtronic, DePuy Synthes, Stryker, Zimmer Biomet, and Smith + Nephew.”
GMED scores 10 today, which Breakaway calls Average. It is #19 of 85 in Medical Devices by Quality Score, with 4 of 14 chart checks firing. Up 2% over five years while the S&P 500 rose 74%; up 30% in the past year. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
GMED scores 10 today, which Breakaway calls Average (6 to 10). That is #19 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GMED's 10.
3 insiders sold $6.4M across 3 filings in the last 6 months. No open-market buys on record. The newest is James R. Tobin, Director, who sold $2.2M on Sep 15. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.